Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-0845-3, published online 29 April 2020
The original version of this article unfortunately contained a mistake in the affiliation of Dr. Delmonte. The correct affiliation should be: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gelsomino, F., Tiseo, M., Barbieri, F. et al. Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL). Br J Cancer 125, 306 (2021). https://doi.org/10.1038/s41416-021-01439-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01439-1
